Analyses of different datasets within the R2 website demonstrated that CRC patients with lower mRNA levels of EBF1 have shorter overall survival (Figure 2A), relapse-free survival (Figure 2B), and event-free survival (Figures 2C–E) compared to those with high EBF1 levels. The gene discussed is EBF1; the disease is colorectal carcinoma.